Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2010
At a glance
- Drugs Aleplasinin (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Wyeth
- 28 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2008 New trial record.
- 28 Jan 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.